Neoadjuvant CTLA-4/PD-(L)1 Blockade Versus Surgery +/- Chemotherapy in Deficient Mismatch Repair/Microsatellite Instability-High Resectable Gastroesophageal Adenocarcinoma: Individual Patient Data Pooled Analysis

Lung, Respiratory and Thoracic Cancer

Long-term overall survival with dual CTLA-4 and PD-L1 or PD-1 blockade and biomarker-based subgroup analyses in patients with advanced non-small-cell lung cancer: a systematic review and reconstructed individual patient data meta-analysis

Lancet Oncol

Di Federico A, Stumpo S, Mantuano F, De Giglio A, Lo Bianco F, Pecci F, Alessi JV, Wang X, Sperandi F, Melotti B, Gelsomino F, Skoulidis F, Garassino MC, Peters S, Awad MM, Ardizzoni A, Ricciuti B

doi: 10.1016/S1470-2045(25)00429-2

Gastrointestinal Cancer

Systemic chemotherapy for patients with resectable or resected colorectal cancer liver metastases: An individual patient data meta-analysis

Eur J Cancer

Bregni G, Leurquin B, Giasafaki P, Takemura N, Kokudo N, Hasegawa K, Matsuyama Y, Nishioka Y, Aparicio T, Guimbaud R, Malicot KL, Tu D, O'Callaghan C, Lutz MP, Fontana E, Moehler M, Mauer ME, Sclafani F

doi: 10.1016/j.ejca.2025.116092

Gastrointestinal Cancer

Mismatch repair deficiency or microsatellite instability in locally advanced rectal cancer patients treated with total neoadjuvant therapy

Eur J Cancer

Benhima N, Audisio A, Gallio C, Ricco G, Meillat H, Velenik V, Riesco MC, Suárez Alecha J, Rasschaert G, Páez López-Bravo D, Tougeron D, Carvalho C, Borelli B, Famiglietti F, De la Pinta C, O'Connor JM, Artaç M, Braam PM, Puccini A, Waldhorn I, Vanden Bulcke A, Loi M, De Felice F, Eid M, Deleporte A, Rossini C, Montenegro P, Fiore M, Van Den Eynde M, Shamseddine A, Geboes KP, Messina M, Mulet Margalef N, Houlzé-Laroye C, Kirac I, Pastorino A, Salati M, Argalácsová S, Morano F, Capdevila J, Garajovà I, Antoun C, Sousa Pinto CM, Lutz MP, Adams RA, Chau A, Siebenhuener A, Dermine A, Ghidini M, Dulskas A, Papamichael D, Javed MA, Ruiz-Garcia E, Tomášek J, Petrillo A, Baratelli C, Vandamme T, Spolverato G, Bock F, Diaz M, Campana LG, Sur D, Karampeazis A, Patsko V, Puleo F, Bounedjar A, Fiorica F, Gilliaux Q, Bernardini I, De Stefano A, Grønlie Guren M, Jakubauskas M, Sert F, Gomez Galdon M, Veron Sanchez A, Vierasu OI, Assaf I, Moretti L, Martinive P, Liberale G, Van Laethem JL, Sclafani F, International Real-World TNT Study Consortium

doi: 10.1016/j.ejca.2026.116911

Lung, Respiratory and Thoracic Cancer

Long-term survival with PD-1/PD-L1 inhibitors plus platinum-based chemotherapy versus chemotherapy alone in locally advanced or metastatic pulmonary lymphoepithelioma-like carcinoma: updated follow-up analysis

Lung Cancer

Tang Y, Du W, Zhang X, Yang X, Zhou Y, Fu S, Zhang L, Hong S

doi: 10.1016/j.lungcan.2025.108855

Gastrointestinal Cancer

FOLFOXIRI/bevacizumab versus doublets/bevacizumab as initial therapy of unresectable liver-only, right-sided and/or RAS or BRAF mutated metastatic colorectal cancer: An individual patient data-based pooled analysis of randomized trials

Eur J Cancer

Antoniotti C, Marmorino F, Rossini D, Schmoll HJ, Lonardi S, Tonini G, Borelli B, Cupini S, Stein A, Moretto R, Bergamo F, Ronzoni M, Germani MM, Zaniboni A, Fazio R, De Grandis MC, Ongaro E, Masi G, Cremolini C

doi: 10.1016/j.ejca.2025.115713

SABCS 2025

Breast Cancer

ASCENT-03: Frontline sacituzumab govitecan improves QoL versus chemotherapy in patients with metastatic TNBC ineligible for PD-1/PD-L1 inhibitors

ESMO 2025

Breast Cancer

ASCENT-03: First-line sacituzumab govitecan improves PFS versus chemotherapy in patients with advanced TNBC ineligible for PD-1/PD-L1 inhibitors

Gynecologic Cancer

Neoadjuvant chemotherapy followed by interval surgery versus primary debulking surgery in FIGO stage III-IV epithelial ovarian cancer: A systematic review and meta-analysis

Eur J Cancer

Secchi M, Signorelli M, Rulli E, Maruccio M, Di Martino G, Spadaro D, Giudice E, Turinetto M, Landoni F, Restaino S, Vizzielli G, Martinelli F, Lorusso D

doi: 10.1016/j.ejca.2025.116116

SPECIAL REPORT

Gynecologic Cancer

Related content

Long-term overall survival with dual CTLA-4 and PD-L1 or PD-1 blockade and biomarker-based subgroup analyses in patients with advanced non-small-cell lung cancer: a systematic review and reconstructed individual patient data meta-analysis

Systemic chemotherapy for patients with resectable or resected colorectal cancer liver metastases: An individual patient data meta-analysis

Mismatch repair deficiency or microsatellite instability in locally advanced rectal cancer patients treated with total neoadjuvant therapy

Long-term survival with PD-1/PD-L1 inhibitors plus platinum-based chemotherapy versus chemotherapy alone in locally advanced or metastatic pulmonary lymphoepithelioma-like carcinoma: updated follow-up analysis

FOLFOXIRI/bevacizumab versus doublets/bevacizumab as initial therapy of unresectable liver-only, right-sided and/or RAS or BRAF mutated metastatic colorectal cancer: An individual patient data-based pooled analysis of randomized trials

ASCENT-03: Frontline sacituzumab govitecan improves QoL versus chemotherapy in patients with metastatic TNBC ineligible for PD-1/PD-L1 inhibitors

ASCENT-03: First-line sacituzumab govitecan improves PFS versus chemotherapy in patients with advanced TNBC ineligible for PD-1/PD-L1 inhibitors

Neoadjuvant chemotherapy followed by interval surgery versus primary debulking surgery in FIGO stage III-IV epithelial ovarian cancer: A systematic review and meta-analysis

Establishing Pembrolizumab Plus Chemotherapy as a New Standard for dMMR Endometrial Cancer